SR Biotech is a company founded on over 20 years of skin absorption technology research, currently led by CEO So-Hyung Lee, a former McKinsey consultant. Since its establishment in 2007, SR Biotech has focused on skin science research and skincare solution development, driving innovation in the global premium skincare market. In particular, the company’s proprietary patented ingredient, ‘Altum Peptide’, has garnered global attention for its exceptional efficacy in wrinkle reduction and skin elasticity enhancement by combining micro spicules with peptides.
SR Biotech is dedicated to nurturing natural skin health and collaborates with leading global universities and research institutions to develop products that integrate the latest biotechnology advancements. The company currently operates the medical professional brand ‘Edenel’ and is set to establish itself as a leader in the global skin health industry.
SR Biotech has rapidly expanded in both domestic and international markets based on the proprietary technology and clinical research of Altum Peptide. The company has secured eight patents in key markets including Europe, Japan, and China, accelerating its global expansion. In addition, SR Biotech continues to develop and produce skincare product lines utilizing its innovative Altum ingredient.
Domestically, Altum Peptide has gained widespread recognition for its high level of reliability and proven effectiveness. The medical aesthetic brand ‘Edenel’, which incorporates Altum technology, is currently used in over 15 dermatology clinics across South Korea. Backed by research and expert consultation from dermatologists, the effectiveness and safety of its products have been well-established.
Internationally, SR Biotech is also expanding its footprint rapidly. Altum Peptide has been patented in more than 20 countries, including South Korea, Japan, the UK, Germany, and France, and has received high praise from customers at major global medical aesthetic and beauty exhibitions. Currently, distribution contracts have been secured in eight countries, and within just one year of launch, monthly sales have grown by 65 times. The company is now focused on expanding into additional markets at an accelerated pace.
SR Biotech is participating in KIMES 2025 (March 20–23) to introduce the professional medical aesthetic brand ‘Edenel’ and the world’s first Micro-Invasive skin booster, ‘Peptaxel’, to a global audience and connect with distributors capable of bringing these products to new markets. Peptaxel is already being distributed in the U.S., Canada, Vietnam, and the Czech Republic, and this exhibition will provide an opportunity to introduce the product to even more markets.
Given the rising global demand for Korean aesthetic treatments and medical devices, SR Biotech is looking forward to meeting international partners at KIMES 2025 to expand its global distribution network.
The key highlight of SR Biotech’s showcase at KIMES 2025 is its groundbreaking skin science technology, featuring Altum Peptide. Altum Peptide penetrates deep beyond the skin barrier, effectively addressing various skin concerns. The technology involves a unique combination of micro spicules and peptides, which naturally releases peptides upon contact with glutathione in the skin, thereby stimulating collagen production and enhancing skin firmness and wrinkle reduction.
Moreover, Altum Peptide technology is based on targeted oncology technology, making it the first-of-its-kind innovation capable of delivering active ingredients directly to the lowest layers of the epidermis. This allows highly effective treatment for wrinkles, skin texture, elasticity, and other concerns, distinguishing it from conventional skincare and medical aesthetic treatments.
One of the most anticipated products at KIMES 2025 is ‘Peptaxel (PEPTAXEL),’ the world’s first Micro-Invasive skin booster. This technology delivers active ingredients deep into the skin without causing damage, providing a breakthrough alternative to traditional treatments.
Another featured product, ‘Glutagen Booster M’, works in conjunction with Peptaxel by enhancing the activation of Altum Peptide. The combined treatment ensures faster, deeper, and more effective peptide delivery, offering clinically proven, superior aesthetic results.
SR Biotech is not confined to any single market but is actively seeking partnerships in diverse countries to expand its brand and technology globally. The company aims to provide customized skincare solutions that cater to various skin concerns, strengthening its competitive edge in the international medical aesthetic market.
Looking ahead, SR Biotech is set to participate in major global exhibitions such as Cosme Tokyo 2025 and Cosmoprof North America Miami 2025, with further plans to exhibit at ACE 2025, IMCAS Americas 2025, and Beauty Düsseldorf 2025. These events will serve as a platform to showcase Altum Peptide technology to a broader audience, connect with global partners, and expand market share.
Additionally, SR Biotech is working on expanding its product line by integrating Altum Needling technology with other active ingredients such as retinol and vitamins, allowing the company to cater to a wider range of consumer needs. The company is committed to continuous R&D and global marketing efforts to solidify its leadership position in the medical aesthetic industry.
Meanwhile, SR Biotech will showcase its innovative medical aesthetic solutions at KIMES 2025, which runs from March 20 to March 23, aiming to strengthen its global partnerships and expand its market reach.